[{"id":"c658257f-75f4-4d06-aee3-2acd2eb60e2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01485861","created_at":"2021-01-17T17:57:48.754Z","updated_at":"2024-07-02T16:35:37.064Z","phase":"Phase 1/2","brief_title":"Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy","source_id_and_acronym":"NCT01485861","lead_sponsor":"Genentech, Inc.","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • ipatasertib (RG7440) • prednisone • apitolisib (GDC-0980)"],"overall_status":"Completed","enrollment":" Enrollment 298","initiation":"Initiation: 01/11/2012","start_date":" 01/11/2012","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 08/31/2022","study_completion_date":" 08/31/2022","last_update_posted":"2023-09-14"},{"id":"5538e537-d6e2-4b8f-95f1-84b82759df58","acronym":"","url":"https://clinicaltrials.gov/study/NCT01437566","created_at":"2021-01-18T05:57:00.009Z","updated_at":"2024-07-02T16:37:28.007Z","phase":"Phase 2","brief_title":"Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy","source_id_and_acronym":"NCT01437566","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • pictilisib (GDC-0941) • apitolisib (GDC-0980)"],"overall_status":"Completed","enrollment":" Enrollment 318","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2016-11-02"},{"id":"fa553290-ef43-4e2b-a59b-54e094eb41ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT01254526","created_at":"2021-01-18T05:03:27.977Z","updated_at":"2024-07-02T16:37:27.818Z","phase":"Phase 1","brief_title":"Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT01254526","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • apitolisib (GDC-0980)"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 07/01/2012","primary_completion_date":" 07/01/2012","study_txt":" Completion: 04/01/2013","study_completion_date":" 04/01/2013","last_update_posted":"2016-11-02"}]